BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 21251147)

  • 1. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
    Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
    J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Echinocandins in invasive candidiasis].
    Glöckner A; Cornely OA
    Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
    Estes KE; Penzak SR; Calis KA; Walsh TJ
    Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of invasive candidiasis with echinocandins.
    Glöckner A; Steinbach A; Vehreschild JJ; Cornely OA
    Mycoses; 2009 Nov; 52(6):476-86. PubMed ID: 19076282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anidulafungin in the treatment of patients with invasive candidiasis.
    Kett DH; Cubillos GF
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
    Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of anidulafungin in critically ill patients].
    Borges Sá M; Garnacho Montero J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():35-43. PubMed ID: 19572433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Austrian clinical practice with anidulafungin in 2008: a multicenter survey.
    Perkhofer S; Hell M; Gustorff B; Von Goedecke A; Illievich U; Kratzer C; Moosbauer W; Wimmer P; Zerlauth U; Nachbaur K; Vogel W; Bellmann R; Schwameis F; Lass-Flörl C
    J Chemother; 2011 Oct; 23(5):285-9. PubMed ID: 22005061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies.
    Kontoyiannis DP; Bassetti M; Nucci M; Capparella MR; Yan JL; Aram J; Hogan PA
    Mycoses; 2017 Oct; 60(10):663-667. PubMed ID: 28597967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?
    Tapısız A
    Expert Rev Anti Infect Ther; 2011 Mar; 9(3):339-46. PubMed ID: 21417873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anidulafungin versus fluconazole for invasive candidiasis.
    Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
    N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives.
    Neoh CF; Slavin M; Chen SC; Stewart K; Kong DC
    Int J Antimicrob Agents; 2014 Mar; 43(3):207-14. PubMed ID: 24670423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Mycoses; 2017 Nov; 60(11):714-722. PubMed ID: 28699297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.
    Ruhnke M; Paiva JA; Meersseman W; Pachl J; Grigoras I; Sganga G; Menichetti F; Montravers P; Auzinger G; Dimopoulos G; Borges Sá M; Miller PJ; Marček T; Kantecki M
    Clin Microbiol Infect; 2012 Jul; 18(7):680-7. PubMed ID: 22404732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.